As a result of the new customer implementation and other positive business developments, CorMedix (CRMD) is increasing its second quarter net sales guidance from the previously communicated $31M to a range of $35M to $40M.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.